Inhibition of Delta-like Ligand 4 enhances the radiosensitivity and inhibits migration in cervical cancer via the reversion of epithelial–mesenchymal transition

BACKGROUND: Concurrent chemoradiotherapy is the common first-line treatment for patients with advanced cervical cancer. However, radioresistance remains a major clinical challenge, which results in recurrence and poor survival. Many studies have shown the potential of Delta-like Ligand 4 (DLL4) as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Shan-Shan, Yu, De-Yang, Du, Yu-Ting, Wang, Le, Gu, Lina, Zhang, Yun-Yan, Xiao, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388465/
https://www.ncbi.nlm.nih.gov/pubmed/32742191
http://dx.doi.org/10.1186/s12935-020-01434-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388465/
https://www.ncbi.nlm.nih.gov/pubmed/32742191
http://dx.doi.org/10.1186/s12935-020-01434-1

Ejemplares similares